MISC

2013年4月

Effects of telmisartan therapy on interleukin-6 and tumor necrosis factor-alpha levels: a meta-analysis of randomized controlled trials

HYPERTENSION RESEARCH
  • Hisato Takagi
  • ,
  • Yusuke Mizuno
  • ,
  • Hirotaka Yamamoto
  • ,
  • Shin-nosuke Goto
  • ,
  • Takuya Umemoto

36
4
開始ページ
368
終了ページ
373
記述言語
英語
掲載種別
DOI
10.1038/hr.2012.196
出版者・発行元
NATURE PUBLISHING GROUP

A recent meta-analysis of randomized head-to-head trials suggests that therapy with telmisartan, an angiotensin II receptor blocker (ARB) and partial agonist of peroxisome proliferator-alpha ctivated receptor-gamma, may increase adiponectin levels more strongly than other ARB therapies. Therefore, telmisartan would be expected to reduce interleukin-6 (IL-6) or tumor necrosis factor-alpha (TNF-alpha). To determine whether telmisartan reduces IL-6 or TNF-alpha, we performed the first meta-analysis of randomized controlled trials of telmisartan therapy. MEDLINE, EMBASE and the Cochrane Central Register of Controlled Trials were searched through November 2011. Eligible studies were prospective randomized controlled trials of telmisartan vs. unrestricted control therapy reporting IL-6 or TNF-alpha levels as an outcome. For each study, data regarding percent changes from baseline to final IL-6 or TNF-alpha levels in both the telmisartan and control groups were used to generate standardized mean differences (SMDs) and 95% confidence intervals (CIs). Nine reports of randomized trials enrolling a total of 645 patients were identified. Pooled analysis of seven and five trials demonstrated a statistically significant reduction in percent changes of IL-6 (fixed-effects SMD, -0.385; 95% CI, -0.581 to -0.189; P<0.001; P for heterogeneity 0.073) and TNF-alpha levels (random-effects SMD, -0.627; 95% CI, -0.945 to -0.308; P<0.001; P for heterogeneity 0.029) with telmisartan relative to control therapy, respectively. In conclusion, based on a meta-analysis of nine randomized controlled trials, telmisartan therapy is likely effective in reducing IL-6 and TNF-alpha levels. Hypertension Research (2013) 36, 368-373; doi: 10.1038/hr.2012.196; published online 13 December 2012

Web of Science ® 被引用回数 : 23

リンク情報
DOI
https://doi.org/10.1038/hr.2012.196
PubMed
https://www.ncbi.nlm.nih.gov/pubmed/23235712
Web of Science
https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcAuth=JSTA_CEL&SrcApp=J_Gate_JST&DestLinkType=FullRecord&KeyUT=WOS:000317105700014&DestApp=WOS_CPL
URL
http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&scp=84877126686&origin=inward
ID情報
  • DOI : 10.1038/hr.2012.196
  • ISSN : 0916-9636
  • PubMed ID : 23235712
  • SCOPUS ID : 84877126686
  • Web of Science ID : WOS:000317105700014

エクスポート
BibTeX RIS